Chiesi Group Appoints David Khougazian as CEO

Chiesi Group has appointed David Khougazian as Group Chief Executive Officer (CEO), effective October 15, 2026.

Maria Paola Chiesi, Chiesi Group Chair, commented: “We are delighted to welcome David to Chiesi at a time of strong momentum for the company. Innovation has always been at the heart of Chiesi’s mission and long-term vision. David’s appointment reflects our ambition to accelerate this journey and strengthen Chiesi’s ability to innovate in a healthcare environment that is changing faster than ever. He brings a unique combination of global healthcare leadership, operational experience and exposure to some of the most dynamic areas of biotech innovation, which makes him exceptionally well positioned to guide Chiesi through this next chapter.”

This appointment comes after Chiesi Group completed its acquisition of KalVista Pharmaceuticals Inc. for approximately $1.9 billion in June.

Experience

Khougazian joins Chiesi following an international career spanning more than 25 years across the global healthcare and life sciences sectors. Most recently, he served as Executive Partner, Growth, and Head of Global Engagement at Flagship Pioneering, where he supported the growth and development of science-driven healthcare companies and worked closely with leadership teams on long-term value creation, partnerships, financing and organizational development.

Khougazian will succeed Interim Group CEO Jean-Marc Bellemin, who has successfully led the Group since May 2026.

“I look forward to working alongside Chiesi colleagues around the world to further strengthen the Group’s innovation capabilities, advance its pipeline and partnerships, and create lasting value for patients, healthcare systems and society,” Khougazian said.